Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

4/28/25 4:22:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JNJ alert in real time by email

Johnson & Johnson (NYSE:JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28^th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time.

A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.

The audio webcast replay will be available approximately 48 hours after the webcast.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250428942864/en/

Media contact:

[email protected]

Investor contact:

[email protected]

Get the next $JNJ alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$JNJ

Date	Price Target	Rating	Analyst
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo
12/1/2023	$167.00 → $180.00	Neutral → Buy	UBS
10/5/2023	$178.00	Outperform	RBC Capital Mkts

More analyst ratings

$JNJ
Press Releases

Fastest customizable press release news feed in the world

Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
Johnson & Johnson (NYSE:JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20250428942864/en/ Media contact: [email protected] Investor contact: [email protected]
4/28/25 4:22:00 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Johnson & Johnson (NYSE:JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a Fireside Chat at 1:35 p.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20250416370813/en/ Media contact: [email protected] Investor contact: [email protected]
4/16/25 4:28:00 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates
NEW YORK, April 15, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on April 15th Bank of America (NYSE: BAC) reported better than expected results this morning, raising share price pre-market.General Motors (NYSE:GM) and Ford (NYSE:F) rose after President Trump's comments around helping auto companiesJohnson & Johnson (NYSE: JNJ), Citigroup (NYSE:C), and PNC (NYSE:PNC) highlight upcoming earningsOpening BellCaterpillar (NYSE:CAT) celebrates its 100th anni
4/15/25 8:55:00 AM ET
$AXS
$BAC
$C
$CAT
Property-Casualty Insurers
Finance
Major Banks
Construction/Ag Equipment/Trucks

$JNJ
Financials

Live finance-specific insights

Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea
4/15/25 6:25:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson Reports Q1 2025 Results
2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the
4/15/25 6:20:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE:JNJ) (the "Company") subsidiary Red River Talc LLC ("Red River") to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants. Rather than pursue a protracted appeal, the Company will return to the tort system to litigate and defeat these merit
3/31/25 10:20:00 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

$JNJ
Leadership Updates

Live Leadership Updates

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines
3/25/25 1:11:06 PM ET
$JNJ
$TVGN
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well
3/4/25 4:15:00 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
GeminiBio Appoints Mike Stella to Board
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
2/18/25 9:00:00 AM ET
$AMGN
$GSK
$JNJ
$MRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components

$JNJ
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

July 21, 2023 - FDA Roundup: July 21, 2023
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
7/21/23 4:02:23 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
5/5/22 4:51:11 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
8/18/21 1:06:11 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

Chat with this insight

Recent Analyst Ratings for $JNJ

$JNJ Press Releases

Fastest customizable press release news feed in the world